NeoPharm CO. LTD (092730) — Financial Flexibility Index
NeoPharm CO. LTD (092730) has a Financial Flexibility Index of 0.33x as of September 2025. Free cash flow of ₩6.32 Billion (operating CF ₩5.88 Billion minus capex ₩446.60 Million) represents 0% of total liabilities (₩18.97 Billion). Also explore 092730 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NeoPharm CO. LTD Financial Flexibility Index (2012–2024)
Historical Financial Flexibility Index trend for NeoPharm CO. LTD across 11 annual periods. Check NeoPharm CO. LTD strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for NeoPharm CO. LTD (2012–2024)
Year-by-year free cash flow to debt coverage for NeoPharm CO. LTD. For the full company profile including market capitalisation, see NeoPharm CO. LTD market capitalisation.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.40x | ₩21.71 Billion | ₩18.63 Billion | ₩15.56 Billion | ▼ -44.8% |
| 2023 | 2.53x | ₩44.09 Billion | ₩23.26 Billion | ₩17.43 Billion | ▲ +75.2% |
| 2022 | 1.44x | ₩18.97 Billion | ₩18.16 Billion | ₩13.14 Billion | ▼ -14.0% |
| 2021 | 1.68x | ₩22.00 Billion | ₩21.68 Billion | ₩13.10 Billion | ▲ +47.6% |
| 2020 | 1.14x | ₩17.36 Billion | ₩17.07 Billion | ₩15.26 Billion | ▼ -22.8% |
| 2019 | 1.47x | ₩25.13 Billion | ₩19.22 Billion | ₩17.05 Billion | ▲ +10.9% |
| 2018 | 1.33x | ₩18.12 Billion | ₩16.18 Billion | ₩13.64 Billion | ▲ +5.0% |
| 2017 | 1.27x | ₩11.53 Billion | ₩10.65 Billion | ₩9.11 Billion | ▼ -4.9% |
| 2016 | 1.33x | ₩10.56 Billion | ₩9.16 Billion | ₩7.94 Billion | ▲ +50.5% |
| 2015 | 0.88x | ₩6.88 Billion | ₩6.09 Billion | ₩7.79 Billion | ▲ +406.0% |
| 2012 | 0.17x | ₩736.81 Million | ₩564.34 Million | ₩4.22 Billion | — |